Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Profit After Tax: 2013-2025

Historic Profit After Tax for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Profit After Tax rose 128.47% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.3 million, marking a year-over-year increase of 159.40%. This contributed to the annual value of -$56.4 million for FY2024, which is 2.22% down from last year.
  • Latest data reveals that Theravance Biopharma reported Profit After Tax of $3.6 million as of Q3 2025, which was down 93.41% from $54.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Profit After Tax ranged from a high of $916.6 million in Q3 2022 and a low of -$86.5 million during Q1 2021.
  • Moreover, its 3-year median value for Profit After Tax was -$12.7 million (2024), whereas its average is -$6.1 million.
  • As far as peak fluctuations go, Theravance Biopharma's Profit After Tax spiked by 1,739.48% in 2022, and later tumbled by 100.98% in 2023.
  • Theravance Biopharma's Profit After Tax (Quarterly) stood at -$57.8 million in 2021, then surged by 75.34% to -$14.3 million in 2022, then skyrocketed by 40.31% to -$8.5 million in 2023, then crashed by 82.46% to -$15.5 million in 2024, then skyrocketed by 128.47% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $54.8 million for Q2 2025, and -$13.6 million during Q1 2025.